Archive Newsletter

  1. 08.20.26 -- Are Biopharma Companies Outsourcing Their Ability To Think? 8/20/2026
    08/20/26 Cell & Gene Newsletter
  2. 08.19.26 -- Building A More Scalable Gene Therapy Program 8/19/2026

    08/19/26 Cell & Gene Newsletter

  3. 08.19.26 -- Scaling Human-Relevant Science For Biologics Development 8/19/2026

    08/19/26 Cell & Gene Newsletter

  4. 08.19.26 -- Redefining Autoimmune Treatment Via Antigen-Specific Immune Tolerance 8/19/2026
    08/19/26 Cell & Gene Newsletter
  5. 08.18.26 -- The Missing Link Between AI Pilots And Production Success 8/18/2026

    08/18/26 Cell & Gene Newsletter

  6. 08.18.26 -- Building Platform Strategies Instead Of One Off Vector Solutions 8/18/2026
    08/18/26 Cell & Gene Newsletter
  7. 08.18.26 -- Reassessing Nanoparticle Immunotoxicity Testing Methods 8/18/2026
    08/18/26 Cell & Gene Newsletter
  8. 08.17.26 -- June 2026 — CDMO Opportunities And Threats Report 8/17/2026
    08/17/26 Cell & Gene Newsletter
  9. 08.14.26 -- The Fast Track to GMP Compliance 8/14/2026
    08/14/26 Cell & Gene Newsletter
  10. 08.14.26 -- The Missing Layer: Why CAR-T Needs AI As Its Connective Tissue 8/14/2026
    08/14/26 Cell & Gene Newsletter